1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007
2. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?;Zhu;Oncologist,2006
3. J.M. Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, AC de Oliveira, A Santoro, JL Raoul, A Forner, M Schwartz, C Porta, S Zeuzem, L Bolondi, TF Greten, PR Galle, JF Seitz, I Borbath, D Häussinger, T Giannaris, M Shan, M Moscovici, D Voliotis, J Bruix, SHARP Investigators Study Group, Sorafenib in advanced hepatocellular carcinoma N Engl J Med, 359 (2008), pp.378–390
4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009
5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017